Cancer News and Research

Latest Cancer News and Research

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Results from the DACO-016 trial of Dacogen (decitabine) in acute myeloid leukemia (AML) were presented today at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)

7 Jun 2011

Renewal Project receives Palo Alto City Council's certification to rebuild, expand Stanford Hospitals

The Palo Alto City Council today voted unanimously to certify the Final Environmental Impact Report (FEIR), grant land use approvals and execute a Development Agreement with Stanford Hospital & Clinics, Lucile Packard Children's Hospital and Stanford University, including a $175 million community benefits package as part of the Renewal Project.

7 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

BioSante Pharmaceuticals, Inc. today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted by FDA.

7 Jun 2011

Independent investigators report Lymphoseek meets all endpoints in NEO3-09 Phase 3 study

Independent investigators reported today full results from the NEO3-09 study, reaffirming earlier top-line results that showed Lymphoseek met all primary and secondary endpoints and exhibited superior performance to vital blue dye in intraoperative lymphatic mapping (ILM) procedures.

7 Jun 2011

Increased blood clotting tendency linked to elevated bowel cancer risk

Back in the mid 19th century, a French doctor, Armand Trousseau, discovered a connection between cancer and thrombosis - the formation of often dangerous blood clots that can lead to venous occlusion.

7 Jun 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

ZIOPHARM Oncology, Inc. announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand.

7 Jun 2011

Study finds decline in low-severity visits after implementation of Massachusetts health care law

While overall emergency department use in Massachusetts continues to rise, the number of low-severity visits dropped slightly since the implementation of the state's health care reform law, according to an Annals of Emergency Medicine study published online.

7 Jun 2011

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

New poll finds 63% of Massachusetts residents support health care law enacted in 2006

A new poll by the Harvard School of Public Health and The Boston Globe finds 63% of Massachusetts residents support the health care reform legislation enacted in 2006, 21% oppose it while 6% are not sure and 9% have not heard or read about the law.

7 Jun 2011

Study finds consistent link between Parkinson's disease and melanoma

An analysis of several studies shows that people with Parkinson's disease have a significantly higher risk of melanoma, the most dangerous type of skin cancer and the leading cause of death from skin diseases.

7 Jun 2011

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

Merck, known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc.,, today announced the presentation of detailed results from the Phase III SUCCEED clinical trial. SUCCEED evaluated oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.

7 Jun 2011

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).

7 Jun 2011

Ovarian cancer screenings do not reduce risk of death

A University of Alabama at Birmingham study released today reports that ovarian cancer screenings do not reduce a woman's risk of death from the disease and the invasive medical procedures may create associated health problems.

7 Jun 2011

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

Circadian Technologies Limited announced today the presentation of data at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago USA associating resistance to Avastin with increases in plasma VEGF-C and D concentrations.

7 Jun 2011

New laboratory method uses SALL4 gene to expand adult hematopoietic stem cells

Researchers in the Department of Pathology at Stony Brook University School of Medicine have discovered a laboratory method to expand adult hematopoietic stem cells (HSCs) using the SALL4 gene. Professor Yupo Ma, M.D., Ph.D., Lead Author, and colleagues used this method to produce a more than 10,000-fold increase in HSCs derived from normal human bone marrow.

7 Jun 2011

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in gastrointestinal stromal tumors (GIST) and a Phase 1 trial of ganetespib in solid tumors evaluating a twice-weekly administration schedule.

7 Jun 2011

Scientists discover key molecule that targets tumour blood vessels

Scientists at the Walter and Eliza Hall Institute have discovered a key molecule needed to kill the blood vessels that supply tumours.

7 Jun 2011

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported updated data from a pivotal trial of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and a phase II trial in relapsed or refractory systemic anaplastic large cell lymphoma.

7 Jun 2011

Faults in p53 gene could help predict beneficial drug combination for ovarian cancer

FAULTS in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to results presented at the American Society for Clinical Oncology.

7 Jun 2011

Cancer News and Research

Latest Cancer News and Research

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Renewal Project receives Palo Alto City Council's certification to rebuild, expand Stanford Hospitals

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

Independent investigators report Lymphoseek meets all endpoints in NEO3-09 Phase 3 study

Increased blood clotting tendency linked to elevated bowel cancer risk

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Study finds decline in low-severity visits after implementation of Massachusetts health care law

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

New poll finds 63% of Massachusetts residents support health care law enacted in 2006

Study finds consistent link between Parkinson's disease and melanoma

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Ovarian cancer screenings do not reduce risk of death

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

New laboratory method uses SALL4 gene to expand adult hematopoietic stem cells

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Scientists discover key molecule that targets tumour blood vessels

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Faults in p53 gene could help predict beneficial drug combination for ovarian cancer

Industry Focus eBook - Immunology (3rd edition) eBook

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Immunology (3rd edition) eBook

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Newsletters you may be interested in